Back to Search Start Over

Open-label pilot study on vitamin D3supplementation for antipsychotic-associated metabolic anomalies

Open-label pilot study on vitamin D3supplementation for antipsychotic-associated metabolic anomalies

Authors :
Thakurathi, Neelam
Stock, Shannon
Oppenheim, Claire E.
Borba, Christina P.C.
Vincenzi, Brenda
Seidman, Larry J.
Stone, William S.
Henderson, David C.
Source :
International Clinical Psychopharmacology; September 2013, Vol. 28 Issue: 5 p275-282, 8p
Publication Year :
2013

Abstract

Previous studies have linked vitamin D deficiency to hypertension, dyslipidemia, diabetes mellitus, and cardiovascular disease. The aim of this study was to investigate the short-term effects of vitamin D3supplementation on weight and glucose and lipid metabolism in antipsychotic-treated patients. A total of 19 schizophrenic or schizoaffective patients (BMI>27 kgm2) taking atypical antipsychotics were recruited and dispensed a 2000 IU daily dose of vitamin D3. On comparing baseline with week 8 (study end) results, we found a statistically significant increase in vitamin D3and total vitamin D levels but no statistically significant changes in weight, glucose, or lipids measurements. Patients whose vitamin D3level at week 8 was 30 ngml or more achieved a significantly greater decrease in total cholesterol levels compared with those whose week 8 vitamin D3measurement was less than 30 ngml. These results suggest that a randomized trial with a longer follow-up period would be helpful in further evaluating the effects of vitamin D3on weight, lipid metabolism, and on components of metabolic syndrome in antipsychotic-treated patients.

Details

Language :
English
ISSN :
02681315 and 14735857
Volume :
28
Issue :
5
Database :
Supplemental Index
Journal :
International Clinical Psychopharmacology
Publication Type :
Periodical
Accession number :
ejs48719775
Full Text :
https://doi.org/10.1097/YIC.0b013e3283628f98